Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$68.54 USD
+4.00 (6.20%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $68.53 -0.01 (-0.01%) 7:40 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.54 USD
+4.00 (6.20%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $68.53 -0.01 (-0.01%) 7:40 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
BioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates
by Zacks Equity Research
BioTelemetry (BEAT) rides high on all its segments in Q2. The company is also putting in efforts in product innovation through research and development.
Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.
Penumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2
by Zacks Equity Research
Penumbra (PEN) witnessed strong growth across all its geographies and product lines in Q2. New product launches raise hope.
C.R. Bard Shareholders Approve Merger With Becton, Dickinson
by Zacks Equity Research
C. R. Bard, Inc. (BCR) announced that the majority of its shareholders have approved its merger with Becton, Dickinson and Company (BDX).
CVS Health (CVS) Q2 Earnings Beat, '17 Guidance Narrowed
by Zacks Equity Research
CVS Health continues to grow (CVS) with Pharmacy Services business. However, its Retail/LTC sales drop.
Henry Schein (HSIC) Q2 Earnings & Revenues Beat, View Intact
by Zacks Equity Research
Henry Schein (HSIC) maintained its stellar performance in Q2 as well, courtesy of strength in all of its business segments.
Orthofix (OFIX) Earnings Meet, Sales Beat Estimates in Q2
by Zacks Equity Research
Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation businesses. Moreover, raised full-year 2017 guidance buoys optimism.
Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Haemonetics (HAE) rides high on Plasma and Haemonetics Management franchises strength in Q1.
Bio-Rad (BIO) Misses Q2 Earnings & Sales, Margin Declines
by Zacks Equity Research
Bio-Rad's (BIO) sales declined on ERP-related disruption. Margin pressure continues.
Cogentix (CGNT) Looks Good: Stock Moves Up 5.2% in Session
by Zacks Equity Research
Cogentix Medical, Inc. (CGNT) moved big mover last session, as its shares rose over 5% on the day.
Cardiovascular Systems Rides on Innovation Amid Several Woes
by Zacks Equity Research
Cardiovascular Systems' (CSII) low operating expenses and strong revenue performance contributed to the upside in Q2 earnings.
Pacific Biosciences (PACB) Posts Wider-than-Expected Q2 Loss
by Zacks Equity Research
Pacific Biosciences (PACB) posted a dull quarter with revenues declining in Q2. However, the company continues to anticipate 35% to 45% growth in product and service revenues for the year.
Wright Medical Group (WMGI) Q2 Loss Narrower than Expected
by Zacks Equity Research
Wright Medical Group N.V. (WMGI) posted narrower-than-expected loss on account of strong growth in the U.S.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Inogen (INGN) delivers better-than-expected results in Q2 with significant contributions from the Business-to-Business segment. Moreover, raised guidance buoys optimism.
Illumina (ILMN) Rides on New Products, Low Margin a Concern
by Zacks Equity Research
Illumina (ILMN) continues to grow in high-potential genetic research market through innovation and product launches.
Bruker (BRKR) Q2 Earnings & Revenues Beat Estimates, View Up
by Zacks Equity Research
Bruker (BRKR) delivers a better-than-expected Q2, largely driven by strength in CALID Group and BEST. Moreover, a raised guidance buoys optimism.
Hologic (HOLX) Beats on 3Q Earnings, Cuts Revenue Guidance
by Zacks Equity Research
Hologic's (HOLX) revenue growth in molecular diagnostics and GYN Surgical offset by poor blood screening and Breast Imaging show.
Cardiovascular Systems (CSII) Posts Q4 Earnings, Revenues Top
by Zacks Equity Research
Cardiovascular Systems' (CSII) lower operating expenses drove the year-over-year improvement in Q4 earnings.
Genomic Health (GHDX) Posts Wider-than-Expected Loss in Q2
by Zacks Equity Research
Genomic Health (GHDX) continues to lag expectations despite strong adoption of its Oncotype DX test.
ResMed (RMD) Q4 Earnings Top, 2020 Strategic Goals on Track
by Zacks Equity Research
ResMed's Q4 results (RMD) register strong sales in sleep devices, respiratory care devices, mask systems and software solutions.
New Strong Buy Stocks for August 1st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
C.R. Bard (BCR) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
C.R. Bard's (BCR) solid performance in the Vascular, Urology and Surgical Specialties were the key highlights of the second quarter.
Edwards Lifesciences (EW) Tops Q2 Earnings & Sales, View Up
by Zacks Equity Research
Edwards Lifesciences (EW) rides high on continued growth in its highly advanced Transcatheter Heart Valve space in Q2.
Edwards Lifesciences (EW) Q2 Earnings: A Surprise in Store?
by Zacks Equity Research
Edwards Lifesciences (EW) will likely ride high in Q2 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve space.
Haemonetics Plasma Arm Advances, Blood Center Sluggish
by Zacks Equity Research
On Jul 13, we issued an updated research report on Haemonetics Corporation (HAE).